Description: Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions primarily in Canada. Its TeloView platform measures the 3D structure and spatial organization of telomeres to inform on genetic and molecular characteristics that are predictive of genomic instability to identify specific disease mechanisms, predict disease risks, and determine effective treatments. Its lead product is TeloView-SMM (Smoldering Multiple Myeloma) for SMM patients with high risk of transition to multiple myeloma (MM). The company also develops TeloView NDMM that predicts newly diagnosed MM patients who may relapse on 1st line therapy; TeloMRD-D Enumaeration that identifies and enumerates MRD cells in post-transplant patients; and TeloViewNG-MRD (Minimal Residual Disease) Profiling for genomic instability profiling of MRD detected cells in post-transplant patients. It has a collaboration agreement with the Mayo Clinic. Telo Genomics Corp. is headquartered in Toronto, Canada.
Home Page: www.telodx.com
MaRS Centre
Toronto,
ON
M5G 1L7
Canada
Phone:
416 673 8487
Officers
| Name | Title |
|---|---|
| Dr. Sabine Mai Ph.D. | Founder, Interim CEO, Chair of the Clinical & Scientific Advisory Board and Director |
| Dr. Sherif Louis MSc, Ph.D., PMP | President & CTO |
| Mr. Christopher Ross CPA, CGA | Chief Financial Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 113.304 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |